Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Mayuresh M. Abhyankar, Barbara J. Mann, Jeffrey M. Sturek, Savannah Brovero, G. Brett Moreau, Anjali Sengar, Crystal M. Richardson, Sayeh Agah, Anna Pomés, Peter M. Kasson, Mark A. Tomai, Christopher B. Fox, William A. Petri
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2021
Sujets:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/da4da1c7c88a4956b31769225afbc2c2
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Documents similaires